Informations sur le produit
- (3,5-Difluorophenyl)Methanaminium
- (3,5-Difluorophenyl)methanamine
- 1-(3,5-Difluorophenyl)Methanamine
- 3,5-Difluorobenzenemethanamine
- 3,5-Difluorobenzyl Amine
- Benzenemethanamine, 3,5-difluoro-
- Difluorobenzylamine6
- [(3,5-Difluorophenyl)methyl]amine
3,5-Difluorobenzylamine (DFBA) is a drug that is being investigated as an inhibitor of HIV integrase. It has been shown to be selective for mitochondrial membrane potential in cells and also inhibits the binding of human immunodeficiency virus type 1 integrase to its cellular receptor. DFBA has been shown to have excellent pharmacokinetic properties and low toxicity in animals. This molecule can be taken orally and is currently undergoing clinical trials for heart disease and other disorders.